Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Filipe Brogueira
Data de Publicação: 2017
Outros Autores: Duarte, Gonçalo Silva, Costa, João, Ferreira, Joaquim J, Wild, Edward J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/33258
Resumo: © 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
id RCAP_28bcc68876ce2ccf1f6d2e87b5154a05
oai_identifier_str oai:repositorio.ul.pt:10451/33258
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?DeutetrabenazineHuntington's diseaseIndirect comparisonMeta‐analysisTetrabenazine© 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Background: Tetrabenazine is the only US Food and Drug Administration‐approved drug for Huntington's disease, and deutetrabenazine was recently tested against placebo. A switching‐trial from tetrabenazine to deutetrabenazine is underway, but no head‐to‐head, blinded, randomized controlled trial is planned. Using meta‐analytical methodology, the authors compared these molecules. Methods: RCTs comparing tetrabenazine or deutetrabenazine with placebo in Huntington's disease were searched. The authors assessed the Cochrane risk‐of‐bias tool, calculated indirect treatment comparisons, and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Results: The evidence network for this report comprised 1 tetrabenazine trial and 1 deutetrabenazine trial, both against placebo. Risk of bias was moderate in both. Participants in the tetrabenazine and deutetrabenazine trials did not differ significantly on motor scores or adverse events. Depression and somnolence scales significantly favored deutetrabenazine. Conclusion: There is low‐quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety. It is important to note that these results are likely to remain the only head‐to‐head comparison between these 2 compounds in Huntington's disease.WileyRepositório da Universidade de LisboaRodrigues, Filipe BrogueiraDuarte, Gonçalo SilvaCosta, JoãoFerreira, Joaquim JWild, Edward J.2018-05-08T14:45:39Z20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/33258engMov Disord Clin Pract. 2017 Jul-Aug; 4(4): 582–5852330-161910.1002/mdc3.12483info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:28:05Zoai:repositorio.ul.pt:10451/33258Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:48:22.296076Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
title Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
spellingShingle Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
Rodrigues, Filipe Brogueira
Deutetrabenazine
Huntington's disease
Indirect comparison
Meta‐analysis
Tetrabenazine
title_short Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
title_full Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
title_fullStr Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
title_full_unstemmed Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
title_sort Tetrabenazine versus deutetrabenazine for Huntington's disease : twins or distant cousins?
author Rodrigues, Filipe Brogueira
author_facet Rodrigues, Filipe Brogueira
Duarte, Gonçalo Silva
Costa, João
Ferreira, Joaquim J
Wild, Edward J.
author_role author
author2 Duarte, Gonçalo Silva
Costa, João
Ferreira, Joaquim J
Wild, Edward J.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Rodrigues, Filipe Brogueira
Duarte, Gonçalo Silva
Costa, João
Ferreira, Joaquim J
Wild, Edward J.
dc.subject.por.fl_str_mv Deutetrabenazine
Huntington's disease
Indirect comparison
Meta‐analysis
Tetrabenazine
topic Deutetrabenazine
Huntington's disease
Indirect comparison
Meta‐analysis
Tetrabenazine
description © 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01T00:00:00Z
2018-05-08T14:45:39Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/33258
url http://hdl.handle.net/10451/33258
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Mov Disord Clin Pract. 2017 Jul-Aug; 4(4): 582–585
2330-1619
10.1002/mdc3.12483
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134413362036736

Registros relacionados